Literature DB >> 25416841

Low-grade fibromyxoid sarcoma mimicking solitary fibrous tumor: a report of two cases.

Sylvia Papp1, Brendan C Dickson, Runjan Chetty.   

Abstract

Low-grade fibromyxoid sarcoma (LGFMS) is an uncommon fibroblastic neoplasm with many morphologic mimics. Solitary fibrous tumor is a more common fibroblastic neoplasm, but the two rarely enter the same differential diagnosis. However, here, we report two unusual cases of LGFMS, containing dilated, hemangiopericytoma-like blood vessels, which prompted diagnostic considerations of solitary fibrous tumor. Both cases presented were confirmed to harbor FUS gene rearrangement, thereby confirming a diagnosis of LGFMS. One case is that of an 18-year-old male with a left forearm mass, and the other a 50-year-old man with a left popliteal mass. While both cases show some histologic features of LGFMS, the non-classical, dilated blood vessel pattern seen here may serve as a diagnostic pitfall, as LGFMS normally exhibits fine, curvilinear blood vessels. To our knowledge, there is only one other report of LGFMS displaying such hemangiopericytoma-like blood vessels. In summary, when encountering a bland spindle cell neoplasm with classic hemangiopericytoma-like blood vessels, it is prudent to consider a diagnosis of LGFMS besides solitary fibrous tumor--particularly in the absence of CD34 immunoreactivity as it may be a rare, mimicking variant of LGFMS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25416841     DOI: 10.1007/s00428-014-1684-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  Solitary fibrous tumor: A pathological enigma and clinical dilemma.

Authors:  Gerald Langman
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

2.  Low-grade fibromyxoid sarcoma.

Authors:  D M Devaney; P Dervan; S O'Neill; D Carney; M Leader
Journal:  Histopathology       Date:  1990-11       Impact factor: 5.087

Review 3.  Low-grade fibromyxoid sarcoma: a brief review.

Authors:  Stephen E Vernon; Pablo A Bejarano
Journal:  Arch Pathol Lab Med       Date:  2006-09       Impact factor: 5.534

4.  MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma.

Authors:  Leona A Doyle; Emely Möller; Paola Dal Cin; Christopher D M Fletcher; Fredrik Mertens; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 5.  Myxoid tumours of soft tissue.

Authors:  J F Graadt van Roggen; P C Hogendoorn; C D Fletcher
Journal:  Histopathology       Date:  1999-10       Impact factor: 5.087

6.  Hyalinizing spindle cell tumor with giant rosettes: a distinctive tumor closely resembling low-grade fibromyxoid sarcoma.

Authors:  K L Lane; R J Shannon; S W Weiss
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

7.  Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population.

Authors:  Steven D Billings; Georgeta Giblen; Julie C Fanburg-Smith
Journal:  Am J Surg Pathol       Date:  2005-02       Impact factor: 6.394

8.  Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation.

Authors:  Robin Reid; M V Chandu de Silva; Lindsay Paterson; Eleanor Ryan; Cyril Fisher
Journal:  Am J Surg Pathol       Date:  2003-09       Impact factor: 6.394

9.  Low grade fibromyxoid sarcoma: clinicopathological analysis of eleven new cases in support of a distinct entity.

Authors:  J R Goodlad; T Mentzel; C D Fletcher
Journal:  Histopathology       Date:  1995-03       Impact factor: 5.087

10.  Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.

Authors:  Juliann Chmielecki; Aimee M Crago; Mara Rosenberg; Rachael O'Connor; Sarah R Walker; Lauren Ambrogio; Daniel Auclair; Aaron McKenna; Michael C Heinrich; David A Frank; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-01-13       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.